MS934

MS934 is a novel improved VHL-recruiting MEK 1/2 PROTAC degrader. MS934 also degrades CRAF. MS934 can be used for the research of variety of human cancers, such as melanoma, nonsmall cell lung cancer (NSCLC), colorectal cancer, primary brain tumors, and hepatocellular carcinoma (Pink: Target protein ligand (HY-168288) ; Black: linker (HY-168289) ; Blue: E3 ligase ligand (HY-112078) ) [1][2][3].

Product Specifications

CAS Number

[2756323-15-4]

UNSPSC

12352005

Target

MEK; PROTACs; Raf

Type

Reference compound

Related Pathways

MAPK/ERK Pathway; PROTAC

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ms934.html

Purity

98.48

Solubility

DMSO : ≥ 50 mg/mL

Smiles

O=C(C1=C(C(F)=C(C=C1)F)NC2=C(C=C(C=C2)I)F)NOCCCCNCCCCCCCCCCCC(N[C@@H](C(C)(C)C)C(N3[C@@H](C[C@H](C3)O)C(N[C@H](C4=CC=C(C5=C(N=CS5)C)C=C4)C)=O)=O)=O

Molecular Formula

C52H69F3IN7O6S

Molecular Weight

1104.11

References & Citations

[1]Hu J, et al. Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders. J Med Chem. 2020 Dec 24;63 (24) :15883-15905. |[2]Herrera-Montávez C, et al. MEK1/2-Targeting PROTACs Promote the Collateral Degradation of CRAF in KRAS Mutant Cells. bioRxiv, 2023: 2023.06. 15.545136.|[3]Kurimchak AM, et al. The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells. Sci Signal. 2022 Aug 30;15 (749) :eabn2707.